Literature DB >> 23292276

Reply to: Effect of axial length on myopic choroidal neovascularization.

Jiang-Hui Wang1, Wei Jiang, Ze-Feng Kang.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23292276     DOI： 10.1007/s00417-012-2251-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

2.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.

Authors:  Alfredo Pece; Vincenzo Isola; Maria Vadalà; Domenica Matranga
Journal:  Retina       Date:  2006-09       Impact factor: 4.256

3.  VEGF is major stimulator in model of choroidal neovascularization.

Authors:  N Kwak; N Okamoto; J M Wood; P A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-09       Impact factor: 4.799

4.  Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

5.  Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Erdem Ergun; Harald Heinzl; Michael Stur
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.